On April 30th, Bloomage Biotechnology Corporation Limited (Bloomage Biotech) released its annual performance report, stating that its revenue in 2023 was approximately 6.076 billion yuan, a decrease of 4.45% year-on-year; the net profit attributable to shareholders of the listed company was about 593 million yuan, a decrease of 38.97% year-on-year; basic earnings per share were 1.23 yuan, a decrease of 39.11% year-on-year.
Among them, the company’s raw material business achieved revenue of 1.129 billion yuan, an increase of 15.22% year-on-year, and the medical terminal business achieved revenue of 1.09 billion yuan, a significant increase of 58.95% year-on-year; the functional skincare product business achieved revenue of 3.757 billion yuan.
In the raw material business sector, thanks to the company’s outstanding performance in domestic and international markets, Bloomage Biotech achieved revenue of 1.129 billion yuan in 2023, an increase of 15.22% year-on-year, with strong growth momentum. Especially, the export sales revenue reached 517 million yuan, an increase of 21.47% year-on-year, indicating significant achievements in Bloomage Biotech’s internationalization strategy and continued expansion of global influence. In the pharmaceutical-grade raw material field, during the reporting period, the company’s sterile-grade HA production line completed trial production, further consolidating its leading position in the high-end HA market.
In the medical terminal business, Bloomage Biotech achieved revenue of 1.09 billion yuan in 2023, a significant increase of 58.95% year-on-year, with a gross profit margin of 82.10%. This achievement is attributed to the in-depth exploration of product differentiation advantages and the improvement of layered anti-aging product combinations in the medical beauty sector. In particular, revenue from skincare medical products reached 747 million yuan, an increase of 60.29% year-on-year. Among them, revenue from differentiated advantage products such as micro-crosslinked lubricious doll needles increased by over 200% year-on-year, and revenue from lubricious fillers increased by over 250% year-on-year, further enhancing market competitiveness.
Additionally, Bloomage Biotech is steadily advancing its internationalization strategy in the aesthetic medicine business. Currently, the company’s medical beauty brands have successfully registered filler products in multiple countries and regions including the European Union, Russia, Thailand, and Peru, and have sold products to 15 countries and regions including Europe, Russian-speaking regions, the Middle East, and the Americas.
During the reporting period, the functional skincare product business achieved revenue of 3.757 billion yuan, a decrease of 18.45% year-on-year, accounting for 61.84% of the company’s main business revenue. Currently, Bloomage Biotech owns multiple brands including “BIOHYALUX”, “QUADHA”, “Bio-MESO”, “And MEDREPAIR”, covering essence, creams, lotions, masks, hand masks, eye masks, sprays, scalp care, maternity, and baby care, men’s care, and some makeup products. Among them, “BIOHYALUX” focuses on hyaluronic acid technology for aesthetic repair; “QUADHA” focuses on precise skincare and hardcore anti-aging; “Bio-MESO” focuses on skincare for oily skin; “MEDREPAIR” focuses on deep cultivation of sensitive skin.
Bloomage Biotech stated that the company is actively undergoing strategic adjustments, committed to optimizing the category system centered on flagship products, deepening brand value, and strengthening the overall management of multi-brand resources. At the same time, the company is adjusting its channel structure, and increasing the proportion of self-operated channels to improve operational efficiency. These measures will help major brands carry out differentiated operations and orderly growth, gradually growing into national brands.
